# Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

Source: https://onco.cc/trials/nct07808151/  
OnCo record `nct07808151` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab in colorectal cancer, run by Solstice Oncology, Inc., not yet recruiting.

## Summary

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer is a phase 2, randomised interventional study registered as NCT07808151 by Solstice Oncology, Inc., with a registry enrolment figure of 100 participants, started 2026-09-30 and due to reach its primary completion in 2029-09-30. Interventions recorded: Pembrolizumab; Porustobart. Conditions listed: Colon Cancer; Microsatellite Stable (MSS) Colon Cancer; Proficient Mismatch Repair (pMMR) Colon Cancer. Primary outcome: Major Pathologic Response (MPR) rate by Blinded Independent Pathologic Review (BIPR). Colorectal eligibility wording from the registry: "Adenocarcinoma of the colon (rectosigmoid considered non-rectal); pMMR/MSS status". Sites: Belgium, Italy, Netherlands, Spain, United Kingdom, United States. United Kingdom sites listed: 5. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07808151
- Phase: 2
- Setting: A Phase 2, Open-Label, Multicenter, Randomized Trial Evaluating the Efficacy and Safety of Different Schedules of Neoadjuvant Pembrolizumab and Porustobart in Patients With Resectable pMMR/MSS Colon Cancer
- Sponsor: Solstice Oncology, Inc.
- Enrolled: 100

## Notes

- UK sites (registry): Investigator Site (Aberdeen); Investigator Site (Cardiff); Investigator Site (Glasgow); Investigator Site (Leeds); Investigator Site (London).

## Sources

- ClinicalTrials.gov NCT07808151: https://clinicaltrials.gov/study/NCT07808151

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07808151.json